Principal Investigator: Dr Craig Teerlink
University of Utah, Salt Lake City, Utah, USATags: 43460, cancer, genetics/genotyping, halotypes, identity-by-descent, Imputation, segregation
The University of Utah has collected DNA samples on ~10,000 cancer subjects sampled as pedigrees to investigate the genetic basis of cancer. We propose to use UKBiobank data to confirm genetic discoveries found among the University of Utah’s cancer pedigrees. The availability of UKBiobank data adds great efficiency to our study since we will be able to validate some of our findings without the expense of collecting many thousand additional samples from other cancer patients. We anticipate the project will be completed within 36 months. If successful, the research we are proposing will provide a positive public health impact by expanding our collective knowledge concerning the genetic basis of common cancers and may increase our ability to predict cancer in susceptible individuals in the future.
The University of Utah has amassed ~10,000 DNA samples from high risk cancer families that were predominantly sampled for colorectal cancer, melanoma, prostate cancer, and breast cancer. Approximately half the pedigree members have been genotyped on a high density SNP array at present, and the remaining are expected to be genotyped over the next two years. Pedigree members are of similar population origin as the UKBiobank cohort (e.g., Northern European ancestry). We propose to investigate the genomic architecture that may exist between these cancer families from Utah and the UKBiobank cohort, which contains many instances of common cancers, in an attempt to confirm the risk status of genomic features that are detectable in the pedigree resource. We propose to expand the scope of our project from evaluation of the four common cancers that were the original focus of the pedigree resource to include cancer of any site.
Last updated Feb 3, 2019